IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Data from a few CML patients who were treated with IFN-α, followed by imatinib, shows that these patients achieved prolonged remissions, suggesting the depletion of pathologic LSCs with drug administration (26).